Cargando…
Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
PURPOSE: Treatment with the radiolabelled somatostatin analogue (177)Lu-octreotate results in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine tumours. Adding capecitabine to (177)Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now presen...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668587/ https://www.ncbi.nlm.nih.gov/pubmed/18188559 http://dx.doi.org/10.1007/s00259-007-0688-7 |
_version_ | 1782166186436329472 |
---|---|
author | van Essen, Martijn Krenning, Eric P. Kam, Boen L. de Herder, Wouter W. van Aken, Maarten O. Kwekkeboom, Dik J. |
author_facet | van Essen, Martijn Krenning, Eric P. Kam, Boen L. de Herder, Wouter W. van Aken, Maarten O. Kwekkeboom, Dik J. |
author_sort | van Essen, Martijn |
collection | PubMed |
description | PURPOSE: Treatment with the radiolabelled somatostatin analogue (177)Lu-octreotate results in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine tumours. Adding capecitabine to (177)Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now present the short-term toxicity profile of this novel combination. METHODS: Seven patients were treated with 7.4 GBq (177)Lu-octreotate and capecitabine (1650 mg/m(2) per day) for 2 weeks with an intended number of four cycles. Toxicity, and especially haematological and renal parameters, were monitored on a weekly basis for the first two cycles and 4 and 6 weeks after subsequent cycles. RESULTS: None of the patients had hand-foot syndrome. One patient had grade 1 stomatitis occurring after one of four cycles. Grade 3 or 4 leukopenia or neutropenia did not occur. One patient had grade 3 anaemia, but none had grade 4 anaemia. One patient had grade 2 thrombocytopenia after the fourth cycle, and one had grade 3 thrombocytopenia. Grade 4 thrombocytopenia did not occur. No significant changes in serum creatinine levels were observed. None of the patients had symptoms of cardiac ischaemia. CONCLUSIONS: Treatment with the combination of (177)Lu-octreotate and capecitabine was feasible and safe considering acute and subacute side effects. We therefore started a randomised, controlled clinical trial to compare this combination with (177)Lu-octreotate as single agent with regard to anti-tumour effects and side effects. |
format | Text |
id | pubmed-2668587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-26685872009-04-23 Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours van Essen, Martijn Krenning, Eric P. Kam, Boen L. de Herder, Wouter W. van Aken, Maarten O. Kwekkeboom, Dik J. Eur J Nucl Med Mol Imaging Original Article PURPOSE: Treatment with the radiolabelled somatostatin analogue (177)Lu-octreotate results in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine tumours. Adding capecitabine to (177)Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now present the short-term toxicity profile of this novel combination. METHODS: Seven patients were treated with 7.4 GBq (177)Lu-octreotate and capecitabine (1650 mg/m(2) per day) for 2 weeks with an intended number of four cycles. Toxicity, and especially haematological and renal parameters, were monitored on a weekly basis for the first two cycles and 4 and 6 weeks after subsequent cycles. RESULTS: None of the patients had hand-foot syndrome. One patient had grade 1 stomatitis occurring after one of four cycles. Grade 3 or 4 leukopenia or neutropenia did not occur. One patient had grade 3 anaemia, but none had grade 4 anaemia. One patient had grade 2 thrombocytopenia after the fourth cycle, and one had grade 3 thrombocytopenia. Grade 4 thrombocytopenia did not occur. No significant changes in serum creatinine levels were observed. None of the patients had symptoms of cardiac ischaemia. CONCLUSIONS: Treatment with the combination of (177)Lu-octreotate and capecitabine was feasible and safe considering acute and subacute side effects. We therefore started a randomised, controlled clinical trial to compare this combination with (177)Lu-octreotate as single agent with regard to anti-tumour effects and side effects. Springer Berlin Heidelberg 2008-01-11 2008 /pmc/articles/PMC2668587/ /pubmed/18188559 http://dx.doi.org/10.1007/s00259-007-0688-7 Text en © The Author(s) 2007 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Original Article van Essen, Martijn Krenning, Eric P. Kam, Boen L. de Herder, Wouter W. van Aken, Maarten O. Kwekkeboom, Dik J. Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours |
title | Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours |
title_full | Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours |
title_fullStr | Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours |
title_full_unstemmed | Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours |
title_short | Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours |
title_sort | report on short-term side effects of treatments with (177)lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668587/ https://www.ncbi.nlm.nih.gov/pubmed/18188559 http://dx.doi.org/10.1007/s00259-007-0688-7 |
work_keys_str_mv | AT vanessenmartijn reportonshorttermsideeffectsoftreatmentswith177luoctreotateincombinationwithcapecitabineinsevenpatientswithgastroenteropancreaticneuroendocrinetumours AT krenningericp reportonshorttermsideeffectsoftreatmentswith177luoctreotateincombinationwithcapecitabineinsevenpatientswithgastroenteropancreaticneuroendocrinetumours AT kamboenl reportonshorttermsideeffectsoftreatmentswith177luoctreotateincombinationwithcapecitabineinsevenpatientswithgastroenteropancreaticneuroendocrinetumours AT deherderwouterw reportonshorttermsideeffectsoftreatmentswith177luoctreotateincombinationwithcapecitabineinsevenpatientswithgastroenteropancreaticneuroendocrinetumours AT vanakenmaarteno reportonshorttermsideeffectsoftreatmentswith177luoctreotateincombinationwithcapecitabineinsevenpatientswithgastroenteropancreaticneuroendocrinetumours AT kwekkeboomdikj reportonshorttermsideeffectsoftreatmentswith177luoctreotateincombinationwithcapecitabineinsevenpatientswithgastroenteropancreaticneuroendocrinetumours |